Want to see VTGN full AI Analyst Report?
VTGN Stock Chart & Stats
$0.23
<$0.01(1.46%)
At close: 4:00 PM EDT
$0.23
<$0.01(1.46%)
Day’s Range― - ―
52-Week Range$0.20 - $5.14
Previous CloseN/A
Volume374.63K
Average Volume (3M)1.23M
Market Cap
$9.89M
Enterprise Value-$21.72
Total Cash (Recent Filing)$45.40M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding41,032,450
10 Day Avg. Volume1,055,596
30 Day Avg. Volume1,225,812
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.61
Price to Sales (P/S)17.15
P/FCF Ratio-0.33
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside334.78% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$500.00K
Bulls Say, Bears Say
Bulls Say
Differentiated Nose-to-brain MechanismVistaGen's pherine platform is non-systemic and targets nose-to-brain pathways, a structural scientific differentiation versus systemic anxiolytics. That mechanism can yield a favorable safety/abuse profile, support distinct labeling and payer arguments, and sustain competitive advantage if efficacy is proven.
Robust Long-term Safety DatabaseMeeting and exceeding ICH E1 exposure thresholds builds durable safety evidence for chronic use. A substantial long-term exposure record reduces regulatory uncertainty for multi-dose registrational strategies and supports a transition from acute to longer-term treatment pathways.
Stronger Clinical Leadership & GovernanceAddition of an experienced neuroscience executive, plus a new CMO hire reported in the pack, materially strengthens clinical, regulatory and development leadership. Improved governance and clinical expertise increase likelihood of sound trial design, regulatory alignment, and efficient program execution over coming months.
Bears Say
PALISADE-4 Phase 3 FailureA Phase 3 miss is a durable negative: it lowers near-term approval probability, forces a strategic pivot to a different registrational pathway, requires additional trial design and endpoints work, and extends timelines and costs needed to reach commercialization.
Widening Losses And Cash BurnLosses and operating cash consumption have grown materially, translating into real burn rather than non-cash items. Sustained negative cash flow increases reliance on external financing, raises dilution risk, and constrains the company's ability to run multiple late-stage programs simultaneously.
No Recurring Commercial Revenue; Financing DependenceAs a clinical-stage developer without product sales, VistaGen relies on partnerships, milestones and capital markets. That structural financing dependence makes operational plans sensitive to funding availability and heightens execution risk if market conditions or investor appetite weaken.
VistaGen Therapeutics News
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $0.20 and its highest was $5.14 in the past 12 months.
What is VistaGen Therapeutics’s market cap?
VistaGen Therapeutics’s market cap is $9.89M.
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were VistaGen Therapeutics’s earnings last quarter?
VistaGen Therapeutics released its earnings results on Jun 15, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.337 by -$0.033.
Is VistaGen Therapeutics overvalued?
According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does VistaGen Therapeutics have?
VistaGen Therapeutics has 41,032,450 shares outstanding.
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
VistaGen Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.337. Following the earnings report the stock price went up 20.419%.
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Currently, no hedge funds are holding shares in VTGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
VTGN Stock 12 Month Forecast
Average Price Target
$1.00
▲(334.78% Upside)
Technical Analysis
MacroGenics
―
Ovid Therapeutics
―
Spero Therapeutics
―
Inhibikase Therapeutics
―
Surrozen
―
Ownership Overview
0.42% Insiders
4.68% Mutual Funds
0.08% Other Institutional Investors
89.80% Public Companies and
Individual Investors